BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 02/06/2025

Prospective Grant of an Exclusive Patent License: Exceptionally Selective D2 Dopamine Receptor Antagonists as Therapeutics

The National Institute of Neurological Disorders and Stroke and the National Center for Advancing Translational Sciences are contemplating an Exclusive Patent License grant to Psycala Bio, Inc. for inventions related to D2 dopamine receptor antagonists.

Source: Federal Register — Health and Human ServicesOpen original release →